Jobs / United States / Gilead Sciences INC
Exec Director, Viral Vector Process Development
Gilead Sciences INC · 🇺🇸 2 Locations
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 159 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 75 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Gilead Sciences INC paid sponsored hires in similar roles2 certified filings for “Exec Director, Supply Chain” (General and Operations Managers) in CA: $229k–$264k, median $247k. Most were filed at wage level IV (100%) — 4 lottery entries, ≈61% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Gilead Sciences INC
The US Department of Labor certified 159 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 75 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Gilead Sciences INC →
About the role
We’re here for one reason and one reason only – to cure cancer. Every moment is dedicated to developing treatments and every action moves us one step closer to our goal. We’ve made incredible scientific breakthroughs and our pioneering personalized CAR T-cell therapies have changed the paradigm. But we're not finished yet. Join Kite, as we make even bigger advances in cancer therapies, and help shape where our business and medical science goes next. We believe every employee deserves a great leader. People Leaders are the cornerstone to the employee experience at Gilead and Kite. As a people leader now or in the future, you are the key driver in evolving our culture and creating an environment where every employee feels included, developed and empowered to fulfil their aspirations. Join Kite and help create more tomorrows. Job Description This role is accountable for end-to-end viral vector development, from construct design through clinical and commercial manufacturing support, and serves as a key partner across Research, Product Teams, Technical Operations, and Analytical functions. The leader will balance deep technical expertise with executive-level influence, ensuring robust, scalable vector platforms while building a high-performing organization capable of supporting both ex vivo and emerging in vivo applications. Reporting & Location • Reports to: SVP, Global Head of Process Development • Location: Santa Monica, CA Or Oceanside, CA • On-site presence required Key Responsibilities Technical & Scientific Leadership • Accountable for technical strategy for viral vector platforms across clinical and commercial scale, including complex tech transfers, external manufacturing partnerships, and late‑stage manufacturing readiness. • Provide deep expertise in lentiviral vector (LVV) design, including construct architecture, promoter selection, and transgene optimization • Lead viral vector process development, including: • Upstream production systems (transient and stable) • Downstream purification and recovery operations • Drive process scale-up and technology transfer to clinical and commercial manufacturing sites (internal and external) • Oversee LVV life cycle management and manufacturing support capabilities • Lead initiatives to improve viral vector productivity, robustness, and cost of goods • Advance next-generation capabilities, including: • In vivo viral vector development • Platform innovations and emerging delivery technologies Cross-Functional & Product Development Leadership • Ensure viral vector development decisions are optimized across the full cell therapy value chain, from transduction efficiency and cell performance to manufacturing robustness and CMC sustainability. • Provide strategic leadership for viral vector on cross-functional Product Teams • Partner closely with: • Research to translate early concepts into developable and scalable vector designs • T cell process development to align vector performance with cellular outcomes • Analytical development to ensure appropriate characterization and control strategies • Contribute to integrated product development, ensuring vector design and process decisions align with clinical and commercial objectives • Drive alignment across functions in a matrixed environment, balancing competing priorities while maintaining product focus CMC & Regulatory Engagement • Strong working knowledge of cGMP regulations and compliance systems related to viral vector development, including inspection readiness, audit support, and direct engagement with regulatory agencies. • Contribute to LVV CMC strategies, including phase-appropriate viral vector development and scale-up approaches • Support regulatory filings and health authority interactions as a tec